UNSPSC 51342103: Maribavir

This classification denotes a purine antagonist and antiviral agent with the molecular formula C15H19Cl2N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier PTB4X93HE1, chemically known as 5,6-dichloro-n-(1-methylethyl)-1-beta-l-ribofuranosyl-1h-benzimidazol-2-amine but generally known as maribavir, which bears US NIH Compound Identifier 122872. European Medicines Agency schedules Maribavir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03090MIG.

UNSPSC 51342103 Maribavir, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The code nominally describes a specific antiviral pharmaceutical, yet the four recent opportunities in the dataset solicit naloxone, drug deactivation systems, medical and first aid supplies for emergency response, generic pharmaceuticals and OTC products through cooperative purchasing, and direct-to-manufacturer prescription fulfillment services. None of these solicitations reference maribavir or the antiviral drug category the code name implies. The mismatch suggests either a cataloging error in the tagging system or that the code is being used as a catch-all pharmaceutical commodity classifier by state and local agencies without regard to its specific drug designation.

State and local issuing bodies posting under this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), municipal fire departments (City of Tampa), and multi-state cooperative purchasing alliances (Minnesota MMCAP, serving state, local, and participating out-of-state entities including Oregon). Recent opportunities span Florida, Texas, Minnesota, and Oregon, with activity driven primarily by health and emergency services procurement rather than antiviral-specific demand. Representative recent solicitations include Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023), the City of Tampa's IFB for medical and first aid supplies including respiratory equipment and cardiac monitoring devices (due March 13, 2026, with a $700,000 estimated contract value and 5% SLBE bid discount), the Minnesota MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026, with incumbent contracts through June 30, 2028), and the Texas HHS Commission's RFI on direct-to-manufacturer prescription fulfillment (due April 3, 2026). The code shows little relevant recent activity tied to its nominal scope.